Mr James Patrick Bressi, DO | |
4302 Allen Rd, Suite 300, Stow, OH 44224-1032 | |
(330) 945-9551 | |
(330) 945-9920 |
Full Name | Mr James Patrick Bressi |
---|---|
Gender | Male |
Speciality | Pain Medicine - Interventional Pain Medicine |
Location | 4302 Allen Rd, Stow, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659445690 | NPI | - | NPPES |
0766747 | Medicaid | OH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | 34004592B (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr James Patrick Bressi, DO 4302 Allen Rd, Suite 300, Stow, OH 44224-1032 Ph: (330) 945-9551 | Mr James Patrick Bressi, DO 4302 Allen Rd, Suite 300, Stow, OH 44224-1032 Ph: (330) 945-9551 |
News Archive
Injectable nanoparticles developed at MIT may someday eliminate the need for patients with Type 1 diabetes to constantly monitor their blood-sugar levels and inject themselves with insulin.
AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet ticagrelor (BRILINTA™/BRILIQUE™) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.
Although important details remain to be negotiated, the legislative leaders and Gov. Deval Patrick, all Democrats, are working toward a plan that would encourage flat "global payments" to networks of providers for keeping patients well, replacing the fee-for-service system that creates incentives for excessive care by paying for each visit and procedure.
Patients with young-onset Type 2 diabetes have worse metabolic control than those with late-onset disease, but they are less likely to receive organ-protective drugs, show data from the Joint Asia Diabetes Evaluation cohort.
› Verified 6 days ago